Lipella pharmaceuticals announces u.s. patent issuance for diagnostic technology

Pittsburgh, june 17, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of u.s. patent no. 12,326,492, titled “systems and methods of detecting interstitial cystitis.
LIPO Ratings Summary
LIPO Quant Ranking